These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
660 related items for PubMed ID: 18675070
1. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure. Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M. Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070 [Abstract] [Full Text] [Related]
2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L. Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [Abstract] [Full Text] [Related]
4. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group. Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208 [Abstract] [Full Text] [Related]
5. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience. Santos SM, Carlos CM, Cabanayan-Casasola CB, Danguilan RA. Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603 [Abstract] [Full Text] [Related]
6. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J. Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355 [Abstract] [Full Text] [Related]
9. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F. Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150 [Abstract] [Full Text] [Related]
10. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation. Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T. Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109 [Abstract] [Full Text] [Related]
11. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A. Transplantation; 2007 Sep 27; 84(6):706-14. PubMed ID: 17893603 [Abstract] [Full Text] [Related]
12. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine. Kahan BD. Transplant Proc; 2008 Dec 27; 40(10 Suppl):S17-20. PubMed ID: 19100899 [Abstract] [Full Text] [Related]